Anavex Life Sciences
AVXL
Anavex Life Sciences (AVXL) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Dec 31, 2025
- EPS actual
- −$0.06
- EPS estimate
- −$0.12
- EPS surprise
- +51.34%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Feb 9, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | Feb 9, 2026 | −$0.12 | −$0.06 | +51.34% | $0.00 | SEC |
| Q4 2025 | Nov 25, 2025 | −$0.15 | −$0.11 | +26.67% | $0.00 | SEC |
| Q3 2025 | Aug 12, 2025 | −$0.14 | −$0.16 | −12.44% | $0.00 | SEC |
| Q2 2025 | May 13, 2025 | −$0.15 | −$0.13 | +13.33% | $0.00 | SEC |
| Q1 2025 | Feb 12, 2025 | −$0.17 | −$0.14 | +17.65% | $0.00 | SEC |
| Q4 2024 | Dec 23, 2024 | −$0.16 | −$0.14 | +14.27% | $0.00 | SEC |
| Q3 2024 | Aug 6, 2024 | −$0.16 | −$0.14 | +12.50% | $0.00 | SEC |
| Q2 2024 | May 9, 2024 | −$0.11 | −$0.13 | −18.18% | $0.00 | SEC |
| Q1 2024 | Feb 7, 2024 | −$0.15 | −$0.11 | +24.14% | $0.00 | SEC |
| Q4 2023 | Nov 27, 2023 | −$0.15 | −$0.12 | +18.20% | $0.00 | SEC |
| Q3 2023 | Aug 8, 2023 | −$0.17 | −$0.14 | +16.02% | $0.00 | SEC |
| Q2 2023 | May 9, 2023 | −$0.19 | −$0.17 | +9.72% | $0.00 | SEC |
| Q1 2023 | Feb 7, 2023 | −$0.19 | −$0.17 | +9.33% | $0.00 | SEC |
| Q4 2022 | Nov 28, 2022 | −$0.17 | −$0.18 | −9.09% | $0.00 | — |
| Q3 2022 | Aug 9, 2022 | −$0.15 | −$0.16 | −4.03% | $0.00 | — |
| Q2 2022 | May 10, 2022 | −$0.17 | −$0.14 | +16.02% | $0.00 | — |
| Q1 2022 | Feb 9, 2022 | −$0.16 | −$0.14 | +9.68% | $0.00 | — |
| Q4 2021 | Nov 24, 2021 | −$0.15 | −$0.16 | −9.51% | $0.00 | — |
| Q3 2021 | Aug 12, 2021 | −$0.13 | −$0.14 | −4.48% | $0.00 | — |
| Q2 2021 | May 13, 2021 | −$0.13 | −$0.12 | +7.69% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Anavex Life Sciences (AVXL) last report earnings?
Anavex Life Sciences last reported on Feb 9, 2026, covering fiscal Q1 2026.
Did AVXL beat earnings estimates?
Yes. Anavex Life Sciences reported EPS of −$0.06 for Q1 2026 against a −$0.12 estimate — a 51.34% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.